Medimmune Archives

News and Trends 30 Jan 2018

Two Biotechs Team Up to Test their Cancer Antibody Combo in the Clinic

Innate Pharma and MedImmune will test the combination of Innate’s cancer antibody and the checkpoint inhibitor durvalumab in patients with solid tumors. Innate Pharma uses antibodies to enhance the immune system’s ability to fight cancer. It has formed a clinical trial collaboration with the MedImmune, an R&D arm of AstraZeneca. The two companies will share the costs […]

January 30, 2018 - 3 minutesmins - By Alex Dale

News and Trends 6 Apr 2017

How is Biotech Transforming Pharma’s R&D Model?

Since the early 2000s, pharma has undergone a major reorganization. What roles do strategic alliances and acquisitions play in this new model? For almost two centuries, medicinal products have brought continuous therapeutic progress. This path is marked by breakthrough innovations, which now allow us to treat diseases previously believed to be incurable. But to bring about […]

April 6, 2017 - 4 minutesmins - By External Contributor

Best in Biotech 30 Jan 2017

The Shiniest Golden Vertex? 15 Great Biotechs in Cambridge

Cambridge’s image is tied to its Hogwarts-like University and Nobel-hoarding academia, but there’s also an exciting entrepreneurial scene at the cutting edge of technology. We took a look at how big biotech is in the Silicon Fen. Cambridge’s Biotech cluster has an exemplary hive of talent, infrastructure, and capital – enough to create the same vibe […]

January 30, 2017 - 8 minutesmins - By Denise Neves Gameiro

News and Trends 2 Jan 2017

An EU Project will tackle Multiple Sclerosis using Personalized Multi Omics

The MultipleMS Consortium has been granted €15M by the EU Horizon 2020 to improve the treatment of multiple sclerosis using personalized medicine. The EU Horizon 2020 has kicked off the year with a project to develop, validate, and exploit methods for the personalized treatment of multiple sclerosis (MS). The 21 institutions from 12 European countries and […]

January 2, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 1 Dec 2016

7 European Institutions in the Largest Cancer Bioinformatics Collaboration

Europe’s best companies using bioinformatics to tackle cancer will take part in a huge collaboration aimed at developing personalized cancer vaccines. Three biotech companies and four research institutions from Europe are taking part in the Tumor Neoantigen Selection Alliance (TESLA). This is one of the biggest oncology collaborations ever, consisting of 30 organizations and led by […]

December 1, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

cell medimmune influenza a antibody biotech

News and Trends 21 Jul 2016

‘Winner Antibody’ holds promise as universal Influenza A Vaccine

MedImmune and Humabs have reasons to be happy. Their candidate for an Influenza A vaccine has made it into well-known journal, Cell, boasting a unique affinity to the virus with multiple mechanisms to stop infection. The promising candidate is MEDI8852, an antibody initially developed by Humabs (Switzerland). It targets Influenza A virus (the group of viruses known as avian flu), […]

July 21, 2016 - 3 minutesmins - By Denise Neves Gameiro

humabs influenza antibody infectious cellclone medimmune

News and Trends 24 Mar 2016

Novel Antibody for Influenza gets FDA Fast-Track Approval

Humabs (Switzerland) has gotten some serious recognition for its antibody platform, as its candidates for Influenza have received FDA fast-track designation. A biologic therapy for Influenza A has been granted Fast Track Designation by the FDA, a ‘programme to accelerate the treatment commercialisation. The therapy is based on an antibody (MEDI8852) that was initially developed by […]

March 24, 2016 - 3 minutesmins - By Denise Neves Gameiro

ablynx antibodies rsv infection nanobody llama

News and Trends 18 Dec 2015

64 Million RSV Infections Per Year: Perhaps Alpaca Nanobodies Will Save Infant Lives

Ablynx, the Alpaca Nanobody Biotech from Belgium, has completed target enrollment of the first-in-infant Phase I/IIa study with its anti-Respiratory Syncytial virus, which is linked to 3,000-8,500 infant deaths each year. ALX-0171 is a wholly-owned Nanobody drug candidate administered through inhalation (nebulisation), for the treatment of respiratory syncytial virus (RSV) infection in infants. The candidate […]

December 18, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 26 Nov 2015

The UK-Israeli €378M Small-Molecule Offensive Against Migraines

The Israeli TEVA and UK Heptares Therapeutics (now owned by Japanese Sosei) have partnered up on novel drug therapies targeting Migraines. The pain and disruption migraines can cause pain that lasts from 4 to 72 hours, and around 10 million worldwide suffer such episodes on a regular basis. Signs and symptoms of a migraine include photosensitivity […]

November 26, 2015 - 2 minutesmins - By Dani Bancroft

women in biotech movers shakers 2015 biobeats

News and Trends 20 Nov 2015

Get to Know the Top 50 Women in the UK’s Biotech Scene

The Movers & Shakers Report 2015 lists 50 of the Top female Bio-Entrepreneurs… here’s a select few I found particularly impressive in the Biotech Industry! Written by Miranda Weston-Smith, the BioBeat15 report is sponsored by Horton Ruston Poole, Johnson & Johnson Innovation, MedImmune and Pfizer to celebrate what women working in bio-business have brought to […]

November 20, 2015 - 5 minutesmins - By Dani Bancroft

News and Trends 2 Nov 2015

How Big can be Small in Biotech – #BIO-Europe 2015 Keynote

As usual at BIO-Europe, the fair starts with an opening keynote, this time with speakers from Merck Healthcare, MedImmune/AstraZeneca and Baxalta. The keynote is basically a discussion between high-level speakers, akin to the talk which took place in Paris during March, when Antoine Papiernik (the prominent European VC from Sofinnova) led a panel discussion with […]

November 2, 2015 - 5 minutesmins - By Philip Hemme

News and Trends 22 Oct 2015

For when it actually is Lupus: New Autoimmune Crisis Drug reaches Human Trials

ArGEN-X from Ghent (BE) and Breda (NL) has initiated its phase I human trials for Auto-immune diseases such as systemic lupus erythmatosus (SLE) – a rare chronic disease which has had little progress in the last 50 years. Here is the story behind SLE… As a rare disease, Dr. House and his fictional diagnostics team […]

October 22, 2015 - 4 minutesmins - By Dani Bancroft

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us